DanioLabs and Senexis Announce Collaboration on Ageing Related Diseases
DanioLabs has pioneered development of medium/high throughput, high content in vivo assays utilizing its cutting edge zebrafish technology. Known drugs and pharmacological probes are screened with a view to minimizing the risk of drug development. It has two programmes with positive clinical data and a strong preclinical pipeline. DanioLabs has a major neurodegeneration programme covering Parkinson's, Alzheimer's and Huntington's diseases, as well as multiple sclerosis. It is currently screening for small molecules which rescue the underlying pathologies of these disease states as well as ameliorating the cognitive impairment associated with various forms of dementias.
Senexis is developing new chemical entities as inhibitors of amyloid-related toxicity and inflammation in Alzheimer's disease. It is expected that the combination of the two complementary approaches will offer a significant opportunity to develop novel molecules with potential of becoming diseasemodifying therapies for Alzheimer's disease.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.